Immunogenicity Testing Strategy and Bioanalytical Assays for Antibody–Drug Conjugates
Authors:
- 3 May 2013
- journal article
- Published by Taylor & Francis in Bioanalysis
- Vol. 5 (9) , 1041-1055
Abstract
Immunogenicity testing is an important component of clinical development for large-molecule biotherapeutics. New complex types of large molecules, such as antibody-drug conjugates (ADCs), require careful evaluation of the testing strategy and bioanalytical assays used to monitor the development of antitherapeutic antibodies. An electrochemiluminescence-based immunoassay for the detection and epitope characterization of anti-ADC antibodies was validated. Using this assay format, antibodies directed against the monoclonal antibody and linker-drug components of the ADC were successfully detected in a multiple-dose rat toxicity study. Immunogenicity assays incorporating epitope determination may provide additional information about the characteristics of induced antitherapeutic antibodies, including the magnitude and timing of the various types of antibody responses.Keywords
This publication has 22 references indexed in Scilit:
- Targeted Drug Delivery Using ImmunoconjugatesJournal of Immunotherapy, 2011
- Antibody Conjugate Therapeutics: Challenges and PotentialClinical Cancer Research, 2011
- Antibody–drug conjugates: targeted drug delivery for cancerCurrent Opinion in Chemical Biology, 2010
- Immunogenicity of biologically-derived therapeutics: Assessment and interpretation of nonclinical safety studiesRegulatory Toxicology and Pharmacology, 2009
- Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology productsJournal of Pharmaceutical and Biomedical Analysis, 2008
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007
- Scientific and regulatory considerations on the immunogenicity of biologicsTrends in Biotechnology, 2006
- Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology productsJournal of Immunological Methods, 2004
- Immune Responses to Therapeutic Proteins in Humans - Clinical Significance, Assessment and PredictionCurrent Pharmaceutical Biotechnology, 2002
- Immunogenicity of therapeutic proteins: Clinical implications and future prospectsClinical Therapeutics, 2002